XM does not provide services to residents of the United States of America.
B
B

Biogen

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Japan's Eisai developing dementia drug for US market, Nikkei reports

Japan's Eisai developing dementia drug for US market, Nikkei reports TOKYO, June 30 (Reuters) - Japanese drugmaker Eisai 4523.T is developing a d ementia treatment that it aims to commerciali s e in the U.S. by fiscal 2030, the Nikke i r eported on Sunday. The new drug targets a protein called tau, which causes symptoms of Alzheimer's disease, the newspaper reported.
B

Eisai and Biogen launch Alzheimer's drug Leqembi in China

Eisai and Biogen launch Alzheimer's drug Leqembi in China June 28 (Reuters) - Eisai 4523.T and Biogen BIOAb.ST have launched their Alzheimer's treatment Leqembi in China, the third country after the United States and Japan, the companies said on Friday. Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease.
B

Biogen has up to $10 billion for its next M&A bets- Bloomberg News

MEDIA-Biogen has up to $10 billion for its next M&A bets- Bloomberg News -- Source link: https://tinyurl.com/3w57zmcr -- Note: Reuters has not verified this story and does not vouch for its accuracy
B

Tofidence A Biosimilar Referencing Roactemra, Approved In The European Union

BRIEF-Tofidence A Biosimilar Referencing Roactemra, Approved In The European Union June 24 (Reuters) - Biogen Inc BIIB.O : TOFIDENCE™ (TOCILIZUMAB), A BIOSIMILAR REFERENCING ROACTEMRA®, APPROVED IN THE EUROPEAN UNION Source text for Eikon: ID:nGNE95yLRY Further company coverage: BIIB.O
B

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Autodesk Inc ADSK.OQ +6.8% Tesla Inc TSLA.OQ +5.8% Broadcom Inc AVGO.OQ +5.7% Micron Technology Inc MU.OQ +4.7% Synopsys Inc SNPS.OQ +4.0% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -3.2% Atlassian Corp TEAM.OQ -2.4% Biogen Inc BIIB.OQ -2.2% ON Semiconductor Corp ON.OQ -2.0% Marvell Technology Inc MRVL.OQ -1.8% The Nasdaq 100 .NDX gained 287.51 points, or
A
B
B
M
M
T
W
O
U
A
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.